Banque Transatlantique’s Regeneron Pharmaceuticals REGN Stock Holding History

Banque Transatlantique’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$196K	Hold	254	–	–	﹤0.01%	253
2025 Q4	$196K	Hold	254	–	–	﹤0.01%	122
2025 Q3	$143K	Sell	254 -50	-16%	-$28.3K	﹤0.01%	132
2025 Q2	$160K	Sell	304 -50	-14%	-$27.9K	﹤0.01%	120
2025 Q1	$225K	Sell	354 -1,246	-78%	-$857K	0.01%	112
2024 Q4	$1.13M	Buy	+1,600	New	+$1.34M	0.03%	79

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Banque Transatlantique's REGN Position: Q1 2026 in Review

Banque Transatlantique held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 254 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #253.

Banque Transatlantique first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.13M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Banque Transatlantique held 254 shares of Regeneron Pharmaceuticals worth $196K as of Q1 2026.
Banque Transatlantique left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Banque Transatlantique's portfolio in Q1 2026, its #253 holding.
Banque Transatlantique first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Banque Transatlantique's Regeneron Pharmaceuticals position peaked at $1.13M in Q4 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Banque Transatlantique's 13F filing for Q1 2026, filed 13 May 2026.